The most useful questions to ask doctor about semaglutide cover ten areas: thyroid cancer and MEN 2, pancreas and gallbladder history, diabetes medicines and eye disease, kidney health, pregnancy plans, mental health, surgery, other weight-loss medicines, and alcohol. Nothing here is a pass-fail test. Each answer fills in one part of the safety picture so the provider can decide whether semaglutide fits and what follow-up would be needed.

This page explains the review itself. The separate guide to whether semaglutide may fit a person's goals owns the broader candidate question.

Questions to ask doctor about semaglutide: health history

1. Has anyone in the family had medullary thyroid carcinoma or MEN 2?

Medullary thyroid carcinoma (MTC) is a rare thyroid cancer. Multiple endocrine neoplasia syndrome type 2 (MEN 2) is an inherited condition that raises the risk of MTC. The Wegovy prescribing information, revised June 2026, makes a personal or family history of MTC, or MEN 2, a contraindication, meaning the branded medicine isn't used in that situation. The boxed warning comes from thyroid C-cell tumors in rodents; whether that finding applies to people is unknown.

2. Has there ever been pancreatitis?

Pancreatitis means inflammation of the pancreas. The label warns that acute cases have occurred, so a past episode, its cause, and any related records matter to the review. At the same time, a 2024 meta-analysis of randomized semaglutide trials found no higher rate than placebo. Prior pancreatitis still calls for individual judgment because rare trial events cannot answer every person's risk. Our semaglutide and pancreatitis guide covers that evidence in detail.

3. Have there been gallstones, gallbladder inflammation, or gallbladder surgery?

Gallstones and cholecystitis, which means an inflamed gallbladder, occurred more often with Wegovy than placebo in weight-management trials. Rapid or substantial weight loss can also raise gallstone risk. This history helps the provider interpret past abdominal symptoms and decide whether another clinician or record is needed.

Diabetes medicines, eye disease, kidneys, and pregnancy

4. Is diabetes part of the picture, along with insulin, a sulfonylurea, or diabetic eye disease?

A sulfonylurea is a diabetes pill that makes the pancreas release more insulin. Pairing either insulin or a sulfonylurea with semaglutide can raise the chance of hypoglycemia, meaning blood sugar that falls too low.

Eye history matters too. In the 2016 SUSTAIN-6 trial of 3,297 adults with type 2 diabetes at high cardiovascular risk, retinopathy complications occurred in 3.0% with semaglutide and 1.8% with placebo (Marso et al., New England Journal of Medicine). The label says rapid improvement in glucose can temporarily worsen diabetic retinopathy, or damage to the retina at the back of the eye. Existing eye disease and recent treatment give the provider context for monitoring.

5. What is known about kidney function and past dehydration?

The label's kidney warning is mostly about a chain reaction: nausea, vomiting, or diarrhea can reduce body fluid, and that can lead to acute kidney injury, a sudden drop in kidney function. Recent kidney results, prior kidney disease, and a history of becoming dehydrated help the provider judge what follow-up makes sense.

6. Could pregnancy be part of the near-term plan?

For weight reduction, the Wegovy label says treatment is discontinued when pregnancy is recognized and at least two months before a planned pregnancy because semaglutide stays in the body for weeks. Human pregnancy data are not enough to establish drug-associated risk. The intake asks about timing so the provider can discuss the plan rather than discover it after treatment begins. The semaglutide and pregnancy guide explains the label language without turning it into a personal schedule.

Mood, planned procedures, other products, and alcohol

7. Is there a history of depression, suicidal thoughts, or a major mood change?

A complete mental-health history still belongs in a medical intake, but the reason needs current context. As of September 18, 2026, the day this article was written, the current Wegovy label is revised June 2026 and no longer includes the former warning about suicidal behavior and ideation. In January 2026, FDA said its comprehensive review found no increased risk. A pooled analysis of the STEP 1, 2, 3, and 5 trials likewise found no difference from placebo, though those trials excluded people with certain serious psychiatric conditions (Wadden et al., JAMA Internal Medicine, 2024). The provider asks for the real history, not an outdated assumption.

8. Is surgery or a procedure with deep sedation already planned?

Semaglutide can delay stomach emptying. The label records rare aspiration reports, meaning stomach contents entered the lungs during general anesthesia or deep sedation, even after reported fasting. It also says the available data cannot support one universal pause. That is why the medication timeline belongs with both the prescriber and the procedure team; semaglutide before surgery covers the current guidance.

9. Are any other GLP-1 or weight-loss products being used?

Exact names matter, including prescriptions, injections, pills, supplements, and products obtained elsewhere. The Wegovy label does not recommend combining it with another semaglutide product or another GLP-1 receptor agonist. Tirzepatide acts on GLP-1 and a second receptor, so any transition between the two also belongs to the prescriber rather than an online schedule.

10. How much alcohol is typical, and how often?

The label does not list a direct alcohol interaction. The answer still matters because alcohol can complicate low blood sugar for someone using insulin or a sulfonylurea, add to dehydration when stomach symptoms are present, and provide context for a pancreatitis history. The intake needs an ordinary week's pattern, not a moral judgment.

What the answers decide

These questions are meant to uncover firm contraindications, medicine conflicts, missing records, and issues that need another clinician's input. A pause for more information is different from an automatic rejection, and the reviewing provider decides what the answers mean together.

Promise's semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. The actual prescription and pharmacy label govern the formulation and directions.

At Promise, a licensed provider reviews every request and not everyone qualifies.